Dana G. Mead Jr. - 19 Feb 2025 Form 4 Insider Report for Inari Medical, Inc. (NARI)

Role
Director
Signature
/s/ Shannon Trevino, attorney-in-fact for Dana G. Mead, Jr.
Issuer symbol
NARI
Transactions as of
19 Feb 2025
Net transactions value
$0
Form type
4
Filing time
19 Feb 2025, 20:05:29 UTC
Previous filing
05 Jun 2024
Next filing
05 May 2025
SEC
View on sec.gov

Transactions Table

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Ownership Footnotes
transaction NARI Common Stock Disposition pursuant to a tender of shares in a change of control transaction -11,148 -100% 0 19 Feb 2025 Direct F1, F2
* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Dana G. Mead Jr. is no longer subject to Section 16 filing requirements. Form 4 or Form 5 obligations may continue.

Explanation of Responses:

Id Content
F1 Pursuant to the Agreement and Plan of Merger (the "Merger Agreement"), dated January 6, 2025, by and among Stryker Corporation ("Parent"), Eagle 1 Merger Sub, Inc. ("Merger Sub"), and Inari Medical, Inc. ("Issuer") on February 19, 2025 (the "Effective Time"), Merger Sub merged with and into Issuer, with Issuer surviving as a wholly owned subsidiary of Parent upon consummation of the transactions contemplated by the Merger Agreement. At the Effective Time, each outstanding share of common stock of the Issuer ("Common Stock") was cancelled and converted into the right to receive $80.00 in cash (the "Merger Consideration"), without interest.
F2 Includes 4,126 restricted stock units ("RSUs"). At the Effective Time, each outstanding award of RSUs was canceled and converted into the right to receive an amount in cash equal to the product of the aggregate number of shares of Common Stock underlying such RSU immediately prior to the Effective Time, multiplied by the Merger Consideration.